Skip to main content
. 2022 Feb 23;13:768028. doi: 10.3389/fendo.2022.768028

Table 2.

Adverse events in the 47 patients undergoing apatinib for radioiodine-refractory thyroid cancer.

Adverse events Number
All grades Grades 3/4
Hematologic toxicity
Leucopenia 5 1
Granulocytopenia 3 1
Thrombocytopenia 2 1
Non-hematologic toxicity
Hypertension 20 5
Proteinuria 19 5
Hand–foot skin reaction 16 4
Diarrhea 6 2
Liver dysfunction 5 2
Fatigue 5 0
Emesia 4 0
Nausea 3 0
Bleeding 2 0
Bellyache 1 0